AstraZeneca's share dilution gamble on Daiichi drug pays off

AstraZeneca and Daiichi Sankyo's breast cancer drug trastuzumab deruxtecan scored positive results in a trial of metastatic breast cancer patients with recurrent disease following treatment with Roche's Kadcyla. Trastuzumab deruxtecan had "unprecedented clinical activity" in an open-label trial that measured remission rates, although the companies did not disclose detailed data.